Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorBoston Children's Hospital

About this trial

Central line-associated bloodstream infections (CLABSIs) are the most common healthcare-associated infection in children and are associated with morbidity and mortality. This study will attempt to identify the source of bloodstream infections (BSIs) in children with CLABSI because we hypothesize that many of the BSIs that are currently classified as CLABSIs are actually laboratory-confirmed bloodstream infections (LCBI) that may be a result of mucosal barrier injury (MBI), also known as MBI-LCBI. In order to study this, we will isolate bacteria from multiple body sites of children that have BSI in order to compare these bacteria to the strain growing in their blood using whole-genome DNA sequencing. We will also evaluate biomarkers of MBI of the respiratory tract and GI tract.

Eligibility criteria

Qualifiers

Hospitalized at Boston Children's Hospital

Central venous catheter of any type including peripherally inserted central catheters (PICC) in any location.

Laboratory-confirmed bloodstream infection (LCBI) diagnosed by a clinical blood culture growing certain Gram-negative rods

Disqualifiers

Patients with CDC-defined secondary bloodstream infections

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

60 Participants
are grouped into 2 trial groups

Sponsors and collaborators